Clinical experience with somatrem in Japan

Area of Science:

• Endocrinology
• Pediatrics
• Biotechnology

Background:

• Pituitary dwarfism is a condition characterized by insufficient growth hormone production.
• Recombinant DNA technology has enabled the production of human growth hormone (hGH) for therapeutic use.
• Somatrem is a recombinant form of hGH used to treat growth deficiencies.

Purpose of the Study:

• To evaluate the efficacy and safety of somatrem in treating pituitary dwarfism.
• To assess the impact of somatrem on height velocity in pediatric patients.
• To investigate the incidence and effect of anti-hGH antibodies during somatrem treatment.

Main Methods:

• Sixty-two patients with pituitary dwarfism received somatrem at a dosage of 0.5 IU/kg body weight per week.
• Treatment duration ranged from 3 to 14 months.
• Physical, blood, and urine examinations were conducted; anti-hGH antibodies were monitored.

Main Results:

• Height velocity significantly increased from 3.5 +/- 0.9 cm/year to 8.2 +/- 1.7 cm/year during somatrem treatment.
• No significant changes were observed in physical, blood, or urine examinations.
• Anti-hGH antibodies were detected in 62.9% of patients after 3 months and 76.2% after 12 months of treatment.
• Antibody presence did not affect growth rate in 48 of 49 patients with measurable antibodies.

Conclusions:

• Somatrem is an effective treatment for increasing height velocity in children with pituitary dwarfism.
• The development of anti-hGH antibodies during somatrem therapy generally does not compromise growth-promoting effects.
• Recombinant hGH therapy demonstrates a favorable safety profile with no significant adverse findings in routine examinations.